A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin

Vize, C. J., Kim, S. K., Matthews, T., Macsai, M., Merrell, R., Hsu, S., Kundu, M. G., Yoon, J., Kennedy, E., Pai, M., Bain, E., Lassman, A. B., & Moazami, G. (2023). A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin. Ophthalmic Research, 1030–1043. Portico. https://doi.org/10.1159/000531142
Authors:
Colin J. Vize
Stella K. Kim
Tim Matthews
Marian MacSai
Ryan Merrell
Sigmund Hsu
Madan Gopal Kundu
Jennifer Yoon
Emma Kennedy
Madhavi Pai
Earle Bain
Andrew B. Lassman
Golnaz Moazami
Affiliated Authors:
Andrew B. Lassman
Golnaz Moazami
Columbia Affiliation:
Subjects:
Glioblastoma (MeSH)
Gliomas (OpenAlex Topic)
Ocular Cancer Research and Treatment (OpenAlex Topic)
Epidemiology and Treatment of Meningiomas (OpenAlex Topic)
Author Keywords:
antibody-drug conjugate
corneal epitheliopathy
depatuxizumab mafodotin
epidermal growth factor receptor
ocular side effect
ocular sideeffect ·antibody-drugconjugate ·depatuxizumab mafodotin
elink
Publication Type:
Article
Unique ID:
10.1159/000531142
PMID:
37257422
DOI:
10.1159/000531142
Journal:
Ophthalmic Research
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record
View OpenAlex Record
View PubMed Record

Record Created: